Cancer diagnostics often begin with a biopsy and histopathologic examination, from the basis of physical examination and medical history. Sometimes the first indication is an abnormal laboratory test result (eg, anemia resulting from colon cancer).
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
The NIH put Precision Medicine on the map as a revolutionary way to manage disease, delivering the right treatment, to the right patient, at the right time. But what does Precision Medicine r...
Recent advances in genomic technologies have revealed enormous complexities and uniqueness of human physiology. Although enormous efforts are being made to apply this knowledge to enhance the...
Most cancer therapies have highly variable activity from one patient to another, with only a fraction of patients’ cancers responding to a given treatment. In many types of cancer, comb...
It has been noted by many in the community that for Precision Medicine to become a transformative reality, the underlying DNA and RNA sequence data have to become more precise. In my talk, I...
Inherited disorders affect millions of people globally. These diseases significantly impact lives of patients and their families, and in addition, also results in substantial socio-economic i...
Virtually all tumors are genetically heterogeneous, containing subclonal populations of cells that are defined by distinct mutations. Subclones can have unique phenotypes that influence disea...
DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
Tissues in the body are wonderfully organized, with specific arrangements of cells, extracellular matrix, secreted molecules, and fluid flow that synergize that create emergent functions. How...
With growing standards of patient care, clinical testing laboratory across the world are forced to change the way they manage their laboratory operations. More focus is now given to automatio...
The attractiveness of 3D printing technology in the microfluidic field is growing, specifically stereolithographic (SLA) type 3D printers, owing to their low cost, versatility, fast and easy...
Computer vision (CV) has seen rapid growth in many industries, including the life sciences with high-content cell imaging and phenotypic assays. However, many biomolecular and cellular assay...
In this seminar, Dr Elvira will talk about the use of droplet microfluidic technologies for drug discovery. Initially, she will discuss the fundamental concepts of droplet microfluidic techno...
The ultimate limits of diagnostics in biology are the “quantum” units that convey information, e.g. single nucleic acids, proteins, and cells. Microfluidics has emerged as a power...
DATE: May 8, 2019TIME: 12:00am PDT In 2017 the first national cervical screening programs using human papillomavirus (HPV-based) primary screening were implemented. As these progr...
To reduce the global burden diseases causes by infectious disease, including parasites and bacteria, scientists need better information about mechanisms of virulence, immune evasion, and drug...
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
The exponential advents of advances in techniques and types of molecular diagnostic testing, and modifying strategies for these tests, are encouraging; but these evolutions simultaneously con...
Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are d...
The prevailing philosophy in biological testing has been to focus on simple tests with easy to interpret information such as ELISA or lateral flow assays. At the same time, there has been a d...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present our clinical decision support solutions,...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
The NIH put Precision Medicine on the map as a revolutionary way to manage disease, delivering the right treatment, to the right patient, at the right time. But what does Precision Medicine r...
Recent advances in genomic technologies have revealed enormous complexities and uniqueness of human physiology. Although enormous efforts are being made to apply this knowledge to enhance the...
Most cancer therapies have highly variable activity from one patient to another, with only a fraction of patients’ cancers responding to a given treatment. In many types of cancer, comb...
It has been noted by many in the community that for Precision Medicine to become a transformative reality, the underlying DNA and RNA sequence data have to become more precise. In my talk, I...
Inherited disorders affect millions of people globally. These diseases significantly impact lives of patients and their families, and in addition, also results in substantial socio-economic i...
Virtually all tumors are genetically heterogeneous, containing subclonal populations of cells that are defined by distinct mutations. Subclones can have unique phenotypes that influence disea...
DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
Tissues in the body are wonderfully organized, with specific arrangements of cells, extracellular matrix, secreted molecules, and fluid flow that synergize that create emergent functions. How...
With growing standards of patient care, clinical testing laboratory across the world are forced to change the way they manage their laboratory operations. More focus is now given to automatio...
The attractiveness of 3D printing technology in the microfluidic field is growing, specifically stereolithographic (SLA) type 3D printers, owing to their low cost, versatility, fast and easy...
Computer vision (CV) has seen rapid growth in many industries, including the life sciences with high-content cell imaging and phenotypic assays. However, many biomolecular and cellular assay...
In this seminar, Dr Elvira will talk about the use of droplet microfluidic technologies for drug discovery. Initially, she will discuss the fundamental concepts of droplet microfluidic techno...
The ultimate limits of diagnostics in biology are the “quantum” units that convey information, e.g. single nucleic acids, proteins, and cells. Microfluidics has emerged as a power...
DATE: May 8, 2019TIME: 12:00am PDT In 2017 the first national cervical screening programs using human papillomavirus (HPV-based) primary screening were implemented. As these progr...
To reduce the global burden diseases causes by infectious disease, including parasites and bacteria, scientists need better information about mechanisms of virulence, immune evasion, and drug...
Integration of technology is influencing practice in the clinical laboratory and treatment of patients in the clinical practice arena. As laboratories begin to move from a volume to value mod...
The exponential advents of advances in techniques and types of molecular diagnostic testing, and modifying strategies for these tests, are encouraging; but these evolutions simultaneously con...
Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are d...
The prevailing philosophy in biological testing has been to focus on simple tests with easy to interpret information such as ELISA or lateral flow assays. At the same time, there has been a d...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer...
The BRCA1 and BRCA2 genes represent the best examples of the modern understanding of cancer molecular genetics. Testing for germline and somatic mutations in BRCA 1/2 has gradually become com...
QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present our clinical decision support solutions,...
Follow
